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Background/Aims: The use of proton pump inhibitors or 
misoprostol is known to prevent the gastrointestinal compli-
cations of nonsteroidal anti-inflammatory drugs (NSAIDs). 
Rebamipide is known to increase the mucosal generation of 
prostaglandins and to eliminate free oxygen radicals, thus 
enhancing the protective function of the gastric mucosa. 
However, it is unknown whether rebamipide plays a role in 
preventing NSAID-induced gastropathy. The aim of this study 
was to determine the effectiveness of rebamipide compared 
to misoprostol in preventing NSAID-induced gastrointestinal 
complications in patients requiring continuous NSAID treat-
ment. Methods: We studied 479 patients who required con-
tinuous NSAID treatment. The patients were randomly as-
signed to groups that received 100 mg of rebamipide three 
times per day or 200 μg of misoprostol three times per day 
for 12 weeks. The primary endpoint of the analysis was the 
occurrence rate of gastric ulcers, as determined by endosco-
py after 12 weeks of therapy. Results: Of the 479 patients in 
the study, 242 received rebamipide, and 237 received miso-
prostol. Ultimately, 44 patients (18.6%) withdrew from the 
misoprostol group and 25 patients (10.3%) withdrew from 
the rebamipide group. There was a significant difference in 
withdrawal rate between the two groups (p=0.0103). The per 
protocol analysis set was not valid because of the dropout 
rate of the misoprostol group; thus, the intention to treat (ITT) 
analysis set is the main set for the efficacy analysis in this 
study. After 12 weeks, the occurrence rate of gastric ulcers 
was similar in the rebamipide and misoprostol groups (20.3% 
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vs 21.9%, p=0.6497) according to ITT analysis. In addition, 
the therapeutic failure rate was similar in the rebamipide 
and misoprostol groups (13.6% vs 13.1%, p=0.8580). The 
total severity score of the gastrointestinal symptoms was 
significantly lower in the rebamipide group than in the miso-
prostol group (p=0.0002). The amount of antacid used was 
significantly lower in the rebamipide group than in the miso-
prostol group (p=0.0258). Conclusions: Rebamipide can 
prevent gastric ulcers when used with NSAIDs and can de-
crease the gastrointestinal symptoms associated with NSAID 
administration. When the possibility of poor compliance and 
the potential adverse effects of misoprostol are considered, 
rebamipide appears to be a clinically effective and safe alter-
native. (Gut Liver 2014;8:371-379)
Key Words: Anti-inflammatory agents, non-steroidal; Rheu-
matic diseases; Complications; Rebamipide; Misoprostol
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely 
prescribed for several conditions, including rheumatoid arthritis, 
osteoarthritis, and musculoskeletal injuries.1 The administration 
of NSAIDs, however, can cause gastrointestinal complications, 
such as bleeding, ulceration, perforation, and obstruction. The 
factors that increase the risk of NSAID-induced gastrointesti-
nal complications include age over 60 years, concomitant use 
of systemic corticosteroids, or anticoagulants, and a history of 
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peptic ulcer.2-6 NSAID-induced gastrointestinal complications 
are caused by various mechanisms, such as abnormalities in 
prostaglandin-dependent gastric mucosal protection caused by 
decreased gastric mucosal prostaglandins.7
Cyclooxygenase 2 (COX-2) inhibitors, which are known to 
be safer than other NSAIDs, are used to reduce NSAID-induced 
gastrointestinal side effects. Many doubts still exist, however, 
about the clinical safety of COX-2 inhibitors, as illustrated by 
the removal of the COX-2 inhibitor rofecoxib from the market.8 
Cotherapy with misoprostol or proton pump inhibitors (PPIs) is 
another way to prevent NSAID-induced gastrointestinal compli-
cations; however, misoprostol itself can cause side effects, such 
as abdominal pain, diarrhea, and dyspepsia, which can decrease 
medication compliance.1 Long-term PPI administration is also 
problematic because issues such as osteoporosis, aspiration 
pneumonia, and atrophic gastritis may result.9
Rebamipide is an antiulcer drug that protects gastric epithelial 
cells, improves gastric defense mechanisms by increasing gastric 
mucus, increases prostaglandin production, and reduces free ox-
ygen radicals.10-13 In healthy volunteers, rebamipide is effective 
at preventing the gastric injury caused by the administration 
of indomethacin. Although the preventive effects of rebamip-
ide on NSAID-induced gastropathy are equivalent to those of 
misoprostol, rebamipide has been reported to cause fewer side 
effects (e.g., lower incidences of diarrhea, lower abdominal pain, 
and abdominal distension).14,15 The present study evaluated the 
efficacy and safety of rebamipide for preventing gastrointestinal 
complications due to NSAIDs by comparing it with misoprostol 
in a randomized, multicenter, double-blind study of patients 
with a high risk of NSAIDs complications.
MATERIALS AND METHODS
1. Patients
The present study was conducted in patients who presented 
at the Yeouido St. Mary’s Hospital of The Catholic University of 
Korea College of Medicine and 16 other hospitals from January 
2008 to March 2010. The inclusion criteria were patients over 
the age of 19 years who had rheumatoid arthritis, osteoarthritis, 
ankylosing spondylitis, and other joint diseases that require 
continuous administration of NSAIDs for more than 12 weeks. 
Patients with a modified Lanza score below 3 in an upper 
gastrointestinal endoscopy who did not have current gastroin-
testinal symptoms and who had at least one of the following 
ulcer risk factors were selected for the study population: his-
tory of peptic ulcer identified through an upper gastrointestinal 
endoscopy, over the age of 60 years, and concomitant therapy 
with systemic corticosteroids (taking more than 5 mg/day of 
prednisolone or the equivalent dose of steroid).16 The following 
exclusion criteria were used: patients with a history of gastroin-
testinal surgery (except appendectomy); patients with abnormal 
bleeding tendency (abnormalities in platelets or blood clotting 
factors); patients with active gastroduodenal ulcers, gastro-
esophageal reflux disease, gastroesophageal varices, Barrett’s 
esophagus, esophageal strictures, or malignant tumors in an 
upper gastrointestinal endoscopy; patients diagnosed with mal-
absorption within the last 3 months; patients with a history of 
cerebrovascular disease, coronary artery disease, diabetes mel-
litus, pancreatitis, chronic kidney disease, chronic liver disease, 
or malignant tumors; patients who were using medications that 
affect gastrointestinal motility, such as sucralfate, H2-receptor 
antagonists, misoprostol, and prokinetics, within a week of 
participating in the study; patients who were using aspirin or 
anticoagulants; patients who were using a PPI within 2 weeks 
of participating in the study; pregnant or nursing women; and 
women of childbearing age who were not using a medically 
confirmed method of contraception.
Before the clinical trial was conducted, the protocols, in-
formed consent forms, and all other related matters were ap-
proved by the Korea Food and Drug Administration and the 
Institutional Review Board of the corresponding institution that 
was conducting the clinical trial.
2. Methods
This study was as a double-blind, double-dummy, random-
ized, multicenter, parallel comparison clinical trial. This study 
consisted of a screening period for 1 or 2 weeks before enroll-
ment, treatment period for 12 weeks, and safety follow-up peri-
od for the 30 days after last investigational product (IP) admin-
istration (Fig. 1). The subjects who agreed to participate and met 
the inclusion criteria were randomly assigned to either the treat-
ment (rebamipide) or control (misoprostol) group. The treatment 
group received 100 mg of rebamipide three times a day, and 
the control group received 200 μg of misoprostol three times a 
day for 12 weeks. As for NSAIDs, after stopping NSAIDs taken 
currently for 1 to 2 weeks, one of medications in the following, 
which fits a subject, was administered for 12 weeks from the 
randomization day: 100 mg of aceclofenac twice a day, 15 mg 
of meloxicam once a day, or 1,000 mg of nabumetone once a 
day (Table 1). An upper gastrointestinal endoscopy was per-
formed during screening and 12 weeks after the IP administra-
tion to evaluate the efficacy. To evaluate safety, vital signs and 
blood chemistry were assessed during every visit from screening 
period to the last day of IP administration. The subjects with 
major protocol deviation (e.g., less than 80% IP compliance and 
not taking NSAIDs for 5 consecutive days) were excluded from 
the per protocol (PP) analysis set.
Taking the following concomitant medications which can af-
fect the clinical symptoms or efficacy evaluation was prohibited: 
anticholinergic drugs, H2-receptor antagonists, PPIs, sucralfate, 
prokinetics, antacids (except aluminum hydroxide gel, which 
was allowed as a rescue medication), prostaglandin drugs other 
than misoprostol, other drugs affecting gastric acid secretion 
and gastrointestinal motility, anticancer drugs, anticoagulants, 
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and NSAIDs other than those provided by the sponsor.
The primary efficacy endpoint was the occurrence rate of 
gastric ulcer confirmed on gastrointestinal endoscopy that 
was performed 12 weeks after the IP administration. An ulcer 
was defined as an excavated mucosal layer with a diameter of 
greater than 3 mm. The occurrence rate of gastric ulcer was de-
termined with the following equation: (the number of subjects 
with gastric ulcer/the total number of subjects in the analysis 
set)×100. The therapeutic failure rate, the severity of gastrointes-
tinal symptoms, and the amount of antacid used were evaluated 
as secondary efficacy endpoints. Therapeutic failure was defined 
as developing a gastric ulcer or withdrawal due to intractable 
gastrointestinal symptoms, which might be major side effect of 
misoprostol.
The gastrointestinal symptoms consisted of seven items: 
heartburn, abdominal distention, nausea, vomiting, upper ab-
dominal pain, lower abdominal pain, and diarrhea. To compare 
the total severity score of gastrointestinal symptoms between 
the two groups, each item was evaluated as no symptoms (0 
points), mild symptoms (1 point), moderate symptoms (2 points), 
or severe symptoms (3 points). The amount of antacid used 
(the total number of tablets taken) in the two groups during the 
clinical trial was compared.
3. Statistics
From the results of previous clinical studies of misoprostol 
(the control drug), the occurrence rate of gastric ulcer was as-
sumed to be 3.7%. The clinically acceptable margin (δ) for 
noninferiority trial was assumed to be 6.9%1,17 because 6.9% is 
half of 13.8%, which is the difference between the occurrence 
rate of gastric ulcer of placebo (17.5%) and misoprostol (3.7%). 
Assuming a significance level (α) of 0.025 in a one-sided test, 
a statistical power (1-β) of 90%, and a 1:1 treatment to control 
group ratio, the number of subjects (n) required for each group 
was 158. Assuming a dropout rate of 20%, the total number of 
subjects was set to 396 (198 in each group).
The efficacy variables included the occurrence rate of gastric 
ulcer, the frequency and rate of the therapeutic failure. For the 
occurrence rate of gastric ulcer and the therapeutic failure rate, 
frequency and percentage of the occurrence of gastric ulcer 
and the therapeutic failure were obtained, and the comparison 
of their rate between groups were performed using chi-square 
test. A repeated measures analysis of variance was used to 
compare the severity of gastrointestinal symptoms between the 
two groups. A two-sample t-test or Wilcoxon rank sum test was 
used to compare amount of antacid consumption between the 
two groups.
For the percentage of the subjects who experienced adverse 
events (AEs) more than once, a 95% confidence interval was 
obtained and the difference between groups was compared us-
ing chi-square test or Fisher exact test. SAS version 9.1 (SAS 
Institute, Cary, NC, USA) was used to perform the statistical 
analysis.
RESULTS
1. Patient population
A total of 664 patients from 17 sites received a screening test. 
Among the 664 patients, 185 were excluded, and 479 were de-
termined to meet the inclusion criteria. Of the 479 patients, 237 
were randomly assigned to the control (misoprostol) group, and 
242 were assigned to the treatment (rebamipide) group. Four 
hundred seventy-eight subjects received the IP at least once (one 
subject in the misoprostol group did not), and 410 subjects com-
pleted the clinical trial: 193 subjects in the misoprostol group 
and 217 subjects in the rebamipide group (Fig. 2). Sixty-nine of 
Fig. 1. Study design.
AE, adverse event; SAE, serious adverse event; CM, concomitant medication; F/U, follow-up.
Table 1. Nonsteroidal Anti-Inflammatory Drugs That Were Prescribed 
in the PRESENT Study (Intention to Treat Population)
Prescribed NSAIDs
Misoprostol
(n=237)
Rebamipide
(n=242)
Total
(n=479)
p-value*
Aceclofenac (100 mg) 75 (31.7) 60 (24.8) 135 (28.2) 0.2489
Meloxicam (7.5 mg) 117 (49.4) 132 (54.6) 249 (52.0)
Nabumetone (500 mg) 45 (19.0) 50 (20.7) 95 (19.8)
Data are presented as number (%).
NSAID, nonsteroidal anti-inflammatory drug.
*Chi-square test.
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the randomly assigned subjects withdrew from the trial: 44 sub-
jects in the misoprostol group (18.6%) and 25 subjects in the re-
bamipide group (10.3%). The withdrawal rate was significantly 
greater in the misoprostol group compared with the rebamipide 
group (p=0.0103 in a chi-square test). The patients provided the 
following reasons for withdrawal: 14 subjects withdrew because 
of AE (10 in the misoprostol group and four in the rebamipide 
group), four subjects withdrew because of poor protocol compli-
ance (one in the misoprostol group and three in the rebamipide 
group), and 48 subjects withdrew because of the withdrawal due 
to gastrointestinal pain (33 in the misoprostol group and 15 in 
the rebamipide group) (Table 2). Therefore, the major analysis 
set for the efficacy in this study is the intention to treat (ITT) 
analysis set because the PP analysis set is decided as less valid 
than ITT analysis set due to significant difference in the with-
drawal rate in between the two groups. There were no signifi-
cant differences between the groups regarding age, sex, smok-
ing history, ulcer risk factors, or modified Lanza scores from the 
endoscopy. The prevalence of ankylosing spondylitis, however, 
was significantly greater in the misoprostol group (p=0.0358) 
(Table 3).
2. Treatment efficacy 
1) Primary efficacy endpoint
The primary efficacy endpoint was the occurrence rate of 
gastric ulcer from the upper gastrointestinal endoscopy (i.e., the 
percentage of subjects in each analysis set with a confirmed 
gastric ulcer). The subject who missed the gastrointestinal en-
doscopy evaluation in 12 weeks of IP administration due to the 
withdrawal was regarded as the subject with gastric ulcer (ther-
apeutic failure) in the ITT analysis set. The occurrence rate of 
gastric ulcer did not significantly differ in the ITT analysis set: 
21.9% (52/237 subjects) for the misoprostol group and 20.3% 
(49/242 subjects) for the rebamipide group (p=0.6497) (Table 4).
2) Secondary efficacy endpoints
The secondary efficacy endpoints were therapeutic failure 
rate, the severity of gastrointestinal symptoms, and the amount 
of antacid used. The therapeutic failure rates did not signifi-
cantly differ between the two groups: 13.1% (31/237 subjects) 
for the misoprostol group and 13.6% (33/242 subjects) for the 
rebamipide group (p=0.8580) (Table 5).
The total severity score of gastrointestinal symptom in the 
misoprostol group were 0.33±0.59 before IP administration, 
0.80±1.14 at 4 weeks, 0.67±1.19 at 8 weeks, and 0.67±1.24 at 
12 weeks. The total severity scores in the rebamipide group were 
generally lower than those in the misoprostol group: 0.24±0.54 
before IP administration, 0.44±0.92 at 4 weeks, 0.36±0.78 at 
8 weeks, and 0.44±1.05 at 12 weeks. In the repeated measures 
analysis of variance, the severity of gastrointestinal symptoms 
was significantly lower in the rebamipide group compared with 
the misoprostol group (a significant group effect, p=0.0002) 
(Table 6).
In the ITT analysis,the number of antacid tablet was 
11.18±22.79 for the misoprostol group and 7.19±15.49 for the 
rebamipide group (p=0.0258) (Table 7).
Fig. 2. Subject dispositions. *One 
subject had multiple reasons for 
screening failure (inclusion/exclu-
sion criteria were not respected, and 
others).
Table 2. Withdrawal Rates in the PRESENT Study (Intention to Treat 
Population)
Reason for
dropping out
Misoprostol
(n=237)
Rebamipide
(n=242)
Total
(n=479)
p-value*
AEs 10 4 14
Poor compliance with 
the protocol
1 3 4
Consent
 withdrawal†
33 15 48
Other 0 3 3
Total, no. (%) 44 (18.6) 25 (10.3) 69 (14.4) 0.0103
AE, adverse event.
*Chi-squared test; †Intractable gastrointestinal symptoms and insuf-
ficient pain control.
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3. Safety evaluation
The safety evaluation was conducted with the 478 subjects 
who were randomized and received IP at least once. One of 
subjects had excluded on the safety evaluation because the 
subject couldn’t take an IP. All the AEs which occurred in this 
study were classified into nontreatment emergent adverse event 
(non-TEAE) occurring before administration of the IP and from 
the day corresponding to five times the half-life after the last 
administration day until 30 days (after the last administration 
day); and exacerbation of pre-existing symptoms or AEs which 
the subject experienced initially after IP administration (TEAE). 
During the clinical trial period, 805 AEs occurred in 331 of the 
478 subjects (69.3%): 166 misoprostol subjects (70.3%, 400 
events) and 165 rebamipide subjects (68.2%, 405 events). There 
were 720 TEAEs in 319 subjects (66.7%), and the incidence of 
these events did not significantly differ between the groups: 161 
subjects for misoprostol (68.2%, 373 events) and 158 subjects 
for rebamipide (65.3%, 347 events). However, the majority of 
Table 3. Demographic Characteristics of the Study Patients
Characteristic
Misoprostol
(n=237)
Rebamipide
(n=242)
Total
(n=479)
p-value
Age, yr 55.8±12.2 55.8±12.2 55.8±12.2 0.9640*
Sex
  Male 44 (18.6) 42 (17.4) 86 (18.0) 0.8119†
  Female 193 (81.4) 200 (82.6) 393 (82.1)
Smokers‡ 36 (15.2) 42 (17.4) 78 (16.3) 0.5383†
Risk factors
  Peptic ulcer history 27 (11.4) 21 (8.7) 48 (10.0) 0.3627†
  ≥60 Years of age 124 (52.3) 118 (48.8) 242 (50.5) 0.4652†
  Concomitant use of
    systemic corticosteroids
132 (55.7) 153 (63.2) 285 (59.5) 0.0951†
Concomitant disease
  Rheumatoid arthritis 149 (62.9) 160 (66.1) 309 (64.5) 0.5040†
  Osteoarthritis 79 (33.3) 79 (32.6) 158 (33.0) 0.9226†
  Ankylosing spondylitis 14 (5.9) 5 (2.1) 19 (4.0) 0.0358†
  Other§ 43 (18.1) 40 (16.5) 83 (17.3) 0.7174†
Modified Lanza score
 (from the screening endoscopy)
  Grade 0 124 (52.3) 132 (54.6) 256 (53.4) 0.1636†
  Grade 1 48 (20.3) 55 (22.7) 103 (21.5)
  Grade 2 40 (16.9) 24 (9.9) 64 (13.4)
  Grade 3 25 (10.6) 30 (12.4) 55 (11.5)
  Grade 4 0 0 0 
  Grade 5 0 1 (0.4) 1 (0.2)
Data are presented as mean±SD or number (%).
*Two-sample t-test; †Fisher exact test; ‡Smokers were defined as individuals who reported any tobacco use; §Osteoporosis, systemic lupus erythem-
atous, and spinal stenosis; Major deviation from the inclusion criteria.
Table 4. Occurrence Rate of Gastric Ulcer at 12 Weeks
Population
Ulcer prevalence
p-value*
95% two-
sided CIMisoprostol
(n=237)
Rebamipide
(n=242)
ITT† 52 (21.9) 49 (20.3) 0.6497 -9.00-5.61
Data are presented as number (%).
CI, confidence interval; ITT, intention to treat.
*Chi-squared test; †Missing endoscopy results at 12 weeks were con-
sidered to be ulcers.
Table 5. Therapeutic Failure Rates in the Misoprostol and Rebamipide 
Groups
Misoprostol
(n=237)
Rebamipide
(n=242)
p-value*
Therapeutic failure† 31 (13.1) 33 (13.6) 0.8580
Data are presented as number (%).
*Chi-squared test; †Therapeutic failures include gastric ulcers and pa-
tients dropping out because of intractable gastrointestinal symptoms.
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the rebamipide group’s TEAEs were mild (misoprostol group, 
76.1% [284/373 events]; rebamipide group, 85.0% [295/347 
events]), and the proportion of moderate or severe TEAEs was 
higher in the misoprostol group (misoprostol group, 23.9% 
[89/373 events], rebamipide group, 15.0% [52/347 events]) (Table 
8).
The most common adverse drug reaction (ADR) was gastroin-
testinal disorders: 64 subjects (27.1%) in the misoprostol group 
and 47 subjects (19.4%) in the rebamipide group; however, the 
difference was not statistically significant. Nausea was signifi-
cantly more common in the misoprostol group (15 subjects, 
6.4%) compared with the rebamipide group (four subjects, 1.7%) 
(p=0.0095) (Table 9).
Table 6. Gastrointestinal Symptom Severity in the Misoprostol and Rebamipide Groups
Gastrointestinal 
symptoms
Visit
Misoprostol Rebamipide
p-value*
No. Mean±SD No. Mean±SD
ITT (LOCF) Baseline 237 0.33±0.59 242 0.24±0.54 0.0002
4 wk 218 0.80±1.14 236 0.44±0.92
8 wk 218 0.67±1.19 236 0.36±0.78
12 wk 218 0.67±1.24 236 0.44±1.05
ITT, intention to treat; LOCF, last observation carried forward.
*Repeated-measures analysis of variance.
Table 7. Number of Subjects Who Consumed Antacid during the 12 Weeks of Nonsteroidal Anti-Inflammatory Drug Administration
Misoprostol Rebamipide Total p-value
The no. of subjects in the ITT population 237 242 479
Antacid consumption 114 (48.1) 96 (39.7) 210 (43.8) 0.0630*
The total no. of antacid tablets consumed per subject† 11.18±22.79 7.19±15.49 9.16±19.53 0.0258‡
Data are presented as number (%) or mean±SD.
ITT, intention to treat.
*Chi-squared test; †Subjects who did not take antacids were regarded as having taken 0 tablets; ‡Two-sample t-test.
Table 8. Treatment Emergent Adverse Events and Adverse Events in the Rebamipide and Misoprostol Groups
TEAEs AEs*
Misoprostol
(n=236)
Rebamipide
(n=242)
Total
(n=478)
Misoprostol
(n=236)
Rebamipide
(n=242)
Total
(n=478)
Total no., subjects (%) [events] 161 (68.2)
[373]
158 (65.3)
[347]
319 (66.7)
[720]
166 (70.3)
[400]
165 (68.2)
[405]
331 (69.3)
[805]
    Exact 95% CI 61.9-74.1 58.9-71.3 62.3-70.9 64.1-76.1 61.9-74.0 64.9-73.4
    p-value† 0.4988 0.6215
No. of AEs
    Mild 284 (76.1) 295 (85.0) 579 (80.4) 307 (76.8) 347 (85.7) 654 (81.2)
    Moderate 74 (19.8) 45 (13.0) 119 (16.5) 78 (19.5) 48 (11.9) 126 (15.7)
    Severe 15 (4.0) 7 (2.0) 22 (3.1) 15 (3.8) 10 (2.5) 25 (3.1)
Serious AEs,  
subjects (%) [events]
3 (1.3)
[3]
7 (2.9)
[9]
10 (2.1)
[12]
3 (1.3)
[3]
10 (4.1)
[13]
13 (2.7)
[16]
    Exact 95% CI 0.3-3.7 1.2-5.9 1.0-3.8 0.3-3.7 2.0-7.5 1.5-4.6
    p-value† 0.3389 0.0882
Data are presented as number (%).
TEAE, treatment emergent adverse event; AE, adverse event; CI, confidence interval.
*All of the AEs (including the TEAEs) during the study; †Fisher exact test.
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DISCUSSION
Approximately 10% to 60% of patients who take NSAIDs 
experience gastrointestinal symptoms (e.g., abdominal pain, 
heartburn, bloating, and indigestion). Interestingly, 10% to 20% 
of the rheumatoid arthritis patients who start NSAIDs discon-
tinue them due to gastrointestinal symptoms.18 Thus, preventing 
gastrointestinal symptoms (in addition to preventing peptic ul-
cers) is an important treatment goal in patients taking NSAIDs. 
It is difficult to obtain an accurate incidence for NSAID-induced 
ulcers because many cases are asymptomatic. In an upper gas-
trointestinal endoscopy study of patients taking NSAIDs, gastric 
ulcers occurred in 10% to 40% of the patients within the first 3 
months of NSAID use, and duodenal ulcers were reported in 4% 
to 15% of the cases.19
A PP analysis is not regarded as a valid in the current study 
due to the significantly greater number of patients in the miso-
prostol group who withdrew compared with the rebamipide 
group. In a previous lansoprazole study, the ITT results were 
also used as the primary analysis because the PP analysis was 
not valid due to significant difference in the withdrawal rate 
in between the two groups.19 In the ITT analysis of the current 
study, the occurrence rate of gastric ulcer in the misoprostol 
group (21.9%, 52/237 subjects) was not significantly differ-
ent (p=0.6497) from the rate in the rebamipide group (20.3%, 
49/242 subjects).
In a previous study about the efficacy of the PPI drug lanso-
prazole to prevent NSAID-induced gastric ulcers, the percent-
ages of subjects without gastric ulcers after 12 weeks of medica-
tion were 51% for the placebo group, 93% for the misoprostol 
group (200 μg four times/day), 80% for the 15 mg lansoprazole 
group, and 82% for the 30 mg lansoprazole group. Although 
the lansoprazole groups had a significant (p<0.001) gastric ulcer 
protective effect compared with the placebo group, the protec-
tive effect was significantly smaller (p=0.01 and p=0.04 for the 
15 and 30 mg groups, respectively) than the effect of miso-
prostol. However, the misoprostol group had several early trial 
withdrawals due to AEs. When these withdrawals were regarded 
as therapeutic failures, the successful treatment percentages 
were 69% for the misoprostol group, the 15 mg lansoprazole 
group, and the 30 mg lansoprazole group and 35% for the pla-
cebo group.19 Given the low medication compliance and high 
gastrointestinal-related AE rates for misoprostol, lansoprazole 
was judged to have high practical clinical value in patients us-
ing NSAIDs for extended periods; therefore, it was approved by 
the U.S. Food and Drug Administration in November 2011.
The misoprostol group may have more patients who withdrew 
early due to gastrointestinal pain because of gastrointestinal 
symptoms from incipient gastric ulcers. Furthermore, the time to 
the first AE in the patients who dropped out was 36 days for the 
misoprostol group and 56 days for the rebamipide group, and 
the more rapid onset of AEs in the misoprostol group may have 
affected the withdrawal rate (Fig. 3). In addition to misoprostol, 
PPI cotherapy is used to prevent NSAID-induced gastrointesti-
nal injury. According to recent data from Cochrane, the preva-
lence of endoscopically confirmed gastric ulcers after 12 weeks 
of NSAIDs and PPI cotherapy is 12.8% to 19.1%.20 In case of 
misoprostol, the gastric ulcer prevalence due to NSAIDs has 
been found to be 8.1% to 10.5%.17 When a group of patients 
at high risk for gastrointestinal complications received NSAIDs 
for 12 weeks in the current study, the occurrence rate of gastric 
ulcer in the rebamipide group was 11.1% in the PP analysis set, 
which did not differ from previously reported occurrence rate 
of gastric ulcer for PPIs. This result suggests that rebamipide is 
Table 9. Major Treatment Emergent Adverse Events Related to the 
Study Drug of Subjects in Either Treatment Group by System Organ 
Class and Preferred Term
Misoprostol
(n=236)
Rebamipide
(n=242)
Total
(n=478)
p-value*
Total no. of TEAEs 69 (29.2)
[126]
53 (21.9)
[95]
122 (25.5)
[221]
0.0746
Gastrointestinal
 disorders
 
  Upper abdominal
    pain
42 (17.8)
[56]
38 (15.7)
[45]
80 (16.7)
[101]
0.5432
  Abdominal
    distension
12 (5.1)
[12]
8 (3.3)
[9]
20 (4.2)
[21]
0.3680
  Nausea 15 (6.4)
[19]
4 (1.7)
[4]
19 (4.0)
[23]
0.0095
  Diarrhea 10 (4.2)
[11]
5 (2.1)
[10]
15 (3.1)
[21]
0.1980
Data are presented as subjects (%) [events].
TEAE, treatment emergent adverse event.
*Fisher exact test.
Fig. 3. Time to first adverse event (AE) (safe population). 
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able to prevent gastric ulcer complications with an efficacy that 
is similar to that of PPIs when it is administered for 12 weeks to 
patents at high risk for NSAIDs complications. Furthermore, the 
use of rebamipide could be a cost-effective method of prevent-
ing NSAID-induced gastrointestinal complications in Korea.
Even when we regarded the withdrawal due to gastroin-
testinal injuries (the major AE for misoprostol) as a treatment 
failure, the therapeutic failure rates in the misoprostol and the 
rebamipide groups (13.1% and 13.6%, respectively) were not 
significantly different. However, the severity of gastrointestinal 
symptoms in the rebamipide group was significantly lower dur-
ing the 12 weeks of NSAIDs administration. Therefore, rebamip-
ide can effectively improve the gastrointestinal symptoms that 
occur with NSAIDs use. Because misoprostol decreases medica-
tion compliance due to gastrointestinal symptoms from the drug 
itself, rebamipide is thought to be a more appropriate medica-
tion for preventing NSAIDs complications. The rebamipide 
group also had significantly lower antacid consumption. Thus, 
the clinical usefulness of rebamipide is thought to be superior to 
that of misoprostol for patients who take NSAIDs for extended 
periods.
According to the safety analysis, nausea was more common 
in the misoprostol group compared with the rebamipide group. 
Although ADRs during the NSAIDs cotherapy occurred less 
frequently in the rebamipide group compared with the miso-
prostol group, the difference between the two groups was not 
significant. This result was confirmed in the Cochrane Database 
of Systematic Reviews and in the existing literature.20,21 The 
Cochrane Database of Systematic Reviews has reported that 
misoprostol increases the dropout risk due to AEs (especially 
nausea, diarrhea, and abdominal pain) by 1.6-fold.20 Moreover, 
in a 6-month study of the prevention of serious NSAID-induced 
gastrointestinal complications, the early dropout rate due to 
AEs was found to be higher in the misoprostol group (27.4%, 
1,210/4,404 subjects) than the placebo group (20.1%, 896/4,439 
subjects) (p<0.001).21 Consequently, rebamipide can be safely 
used in clinical practice, even when administered with NSAIDs 
for 12 weeks.
 For patients who require continuous administration of 
NSAIDs, the ability of rebamipide to reduce gastric ulcers and 
gastrointestinal symptoms has been recognized, and the results 
are similar to the previously reported effects of PPIs. In particu-
lar, misoprostol (a comparator drug) was associated with a high 
dropout rate due to gastrointestinal side effects, whereas the 
rebamipide group was proven to not be inferior to the misopro-
stol group in the ITT analysis, in which withdrew cases were re-
garded as treatment failures. The misoprostol group had a more 
rapid onset of AEs and more high-severity AEs. To a certain 
extent, these results are believed to be responsible for the high 
dropout rate and the low compliance in the misoprostol group, 
whereas rebamipide was determined to have high clinical safety 
and efficacy for patients who use NSAIDs for extended periods.
In conclusion, cotherapy with the mucosal protective agent 
rebamipide can safely and effectively prevent gastric ulcers in 
high-risk patients who require long-term NSAID administration.
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